A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 Diabetes

Sheng Zhang, Sijiu Liu, Rongya Tao, Dan Wei, Lan Chen, Weihua Shen, Zhi Hong Yu, Lina Wang, David R. Jones, X. Dong, Zhong-Yin Zhang

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Protein tyrosine phosphatases (PTPs) constitute a large family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. A detailed understanding of PTP functions in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific, cell-permeable small-molecule agents. We present a stepwise focused library approach that transforms a weak and general non-hydrolyzable pTyr mimetic (F2Pmp, phosphonodifluoromethyl phenylalanine) into a highly potent and selective inhibitor of PTP-MEG2, an antagonist of hepatic insulin signaling. The crystal structures of the PTP-MEG2-inhibitor complexes provide direct evidence that potent and selective PTP inhibitors can be obtained by introducing molecular diversity into the F2Pmp scaffold to engage both the active site and unique nearby peripheral binding pockets. Importantly, the PTP-MEG2 inhibitor possesses highly efficacious cellular activity and is capable of augmenting insulin signaling and improving insulin sensitivity and glucose homeostasis in diet-induced obese mice. The results indicate that F2Pmp can be converted into highly potent and selective PTP inhibitory agents with excellent in vivo efficacy. Given the general nature of the approach, this strategy should be applicable to other members of the PTP superfamily.

Original languageEnglish
Pages (from-to)18116-18124
Number of pages9
JournalJournal of the American Chemical Society
Volume134
Issue number43
DOIs
StatePublished - Oct 31 2012

Fingerprint

Protein Tyrosine Phosphatases
Phosphatases
Medical problems
Type 2 Diabetes Mellitus
Proteins
Insulin
Therapeutics
Insulin Antagonists
Obese Mice
Phosphorylation
Physiology
Nutrition
Phenylalanine
Scaffolds
Libraries
Tyrosine
Insulin Resistance
Catalytic Domain
Homeostasis
Glucose

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 Diabetes. / Zhang, Sheng; Liu, Sijiu; Tao, Rongya; Wei, Dan; Chen, Lan; Shen, Weihua; Yu, Zhi Hong; Wang, Lina; Jones, David R.; Dong, X.; Zhang, Zhong-Yin.

In: Journal of the American Chemical Society, Vol. 134, No. 43, 31.10.2012, p. 18116-18124.

Research output: Contribution to journalArticle

Zhang, Sheng ; Liu, Sijiu ; Tao, Rongya ; Wei, Dan ; Chen, Lan ; Shen, Weihua ; Yu, Zhi Hong ; Wang, Lina ; Jones, David R. ; Dong, X. ; Zhang, Zhong-Yin. / A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 Diabetes. In: Journal of the American Chemical Society. 2012 ; Vol. 134, No. 43. pp. 18116-18124.
@article{fec617ee74734e39ad42b6e26f54be2b,
title = "A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 Diabetes",
abstract = "Protein tyrosine phosphatases (PTPs) constitute a large family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. A detailed understanding of PTP functions in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific, cell-permeable small-molecule agents. We present a stepwise focused library approach that transforms a weak and general non-hydrolyzable pTyr mimetic (F2Pmp, phosphonodifluoromethyl phenylalanine) into a highly potent and selective inhibitor of PTP-MEG2, an antagonist of hepatic insulin signaling. The crystal structures of the PTP-MEG2-inhibitor complexes provide direct evidence that potent and selective PTP inhibitors can be obtained by introducing molecular diversity into the F2Pmp scaffold to engage both the active site and unique nearby peripheral binding pockets. Importantly, the PTP-MEG2 inhibitor possesses highly efficacious cellular activity and is capable of augmenting insulin signaling and improving insulin sensitivity and glucose homeostasis in diet-induced obese mice. The results indicate that F2Pmp can be converted into highly potent and selective PTP inhibitory agents with excellent in vivo efficacy. Given the general nature of the approach, this strategy should be applicable to other members of the PTP superfamily.",
author = "Sheng Zhang and Sijiu Liu and Rongya Tao and Dan Wei and Lan Chen and Weihua Shen and Yu, {Zhi Hong} and Lina Wang and Jones, {David R.} and X. Dong and Zhong-Yin Zhang",
year = "2012",
month = "10",
day = "31",
doi = "10.1021/ja308212y",
language = "English",
volume = "134",
pages = "18116--18124",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "43",

}

TY - JOUR

T1 - A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 Diabetes

AU - Zhang, Sheng

AU - Liu, Sijiu

AU - Tao, Rongya

AU - Wei, Dan

AU - Chen, Lan

AU - Shen, Weihua

AU - Yu, Zhi Hong

AU - Wang, Lina

AU - Jones, David R.

AU - Dong, X.

AU - Zhang, Zhong-Yin

PY - 2012/10/31

Y1 - 2012/10/31

N2 - Protein tyrosine phosphatases (PTPs) constitute a large family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. A detailed understanding of PTP functions in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific, cell-permeable small-molecule agents. We present a stepwise focused library approach that transforms a weak and general non-hydrolyzable pTyr mimetic (F2Pmp, phosphonodifluoromethyl phenylalanine) into a highly potent and selective inhibitor of PTP-MEG2, an antagonist of hepatic insulin signaling. The crystal structures of the PTP-MEG2-inhibitor complexes provide direct evidence that potent and selective PTP inhibitors can be obtained by introducing molecular diversity into the F2Pmp scaffold to engage both the active site and unique nearby peripheral binding pockets. Importantly, the PTP-MEG2 inhibitor possesses highly efficacious cellular activity and is capable of augmenting insulin signaling and improving insulin sensitivity and glucose homeostasis in diet-induced obese mice. The results indicate that F2Pmp can be converted into highly potent and selective PTP inhibitory agents with excellent in vivo efficacy. Given the general nature of the approach, this strategy should be applicable to other members of the PTP superfamily.

AB - Protein tyrosine phosphatases (PTPs) constitute a large family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. A detailed understanding of PTP functions in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific, cell-permeable small-molecule agents. We present a stepwise focused library approach that transforms a weak and general non-hydrolyzable pTyr mimetic (F2Pmp, phosphonodifluoromethyl phenylalanine) into a highly potent and selective inhibitor of PTP-MEG2, an antagonist of hepatic insulin signaling. The crystal structures of the PTP-MEG2-inhibitor complexes provide direct evidence that potent and selective PTP inhibitors can be obtained by introducing molecular diversity into the F2Pmp scaffold to engage both the active site and unique nearby peripheral binding pockets. Importantly, the PTP-MEG2 inhibitor possesses highly efficacious cellular activity and is capable of augmenting insulin signaling and improving insulin sensitivity and glucose homeostasis in diet-induced obese mice. The results indicate that F2Pmp can be converted into highly potent and selective PTP inhibitory agents with excellent in vivo efficacy. Given the general nature of the approach, this strategy should be applicable to other members of the PTP superfamily.

UR - http://www.scopus.com/inward/record.url?scp=84868088782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868088782&partnerID=8YFLogxK

U2 - 10.1021/ja308212y

DO - 10.1021/ja308212y

M3 - Article

VL - 134

SP - 18116

EP - 18124

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 43

ER -